Claire N. Harrison

TL;DR: The current landscape of novel therapies that are under evaluation for patients with MPN is critically illustrated on the basis of current guidelines, patient risk stratification criteria, and previous experience, looking ahead to the chance of a cure for these disorders.

TL;DR: This updated analysis of JAKARTA2 employs intention‐to‐treat analysis principles without LOCF for all treated patients and for a patient subgroup who met more stringent definitions of prior ruxolitinib failure (Stringent Criteria Cohort).

TL;DR: This study aimed to compare the long-term safety and efficacy of ruxolitinib with best available therapy in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea and assessed the durability of primary composite response, complete haematological remission, Overall survival, patient-reported outcomes, and safety after 5-years of follow-up.

TL;DR: This study suggested that therapies that reduce symptom burden and improve QOL in patients with MPNs are crucial in minimizing disease impact on patient daily lives and showed a need for improved patient-physician communication, standardized monitoring of symptoms, and agreement on treatment goals.

TL;DR: A structured expert-panel consensus panel process is used to define RBC-transfusion-dependence and -independence or improvement and it is suggested these definitions may prove useful to persons studying or treating these diseases.